Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00917
|
|||||
Drug Name |
Amsacrine
|
|||||
Synonyms |
4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; AMSA P-D; Acridinyl Anisidide; Acridinyl anisidide (TN); Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrina [INN-Spanish]; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; Amsacrinum; Amsacrinum [INN-Latin]; Amsidine; Amsidyl; Amsidyl (TN); Amsine; Cain's Acridine; Lamasine; M-AMSA; M-AMSA (TN); MAMSA; Meta-AMSA; Meta-Amsacrine; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; NAMSA; SN 21429; SN-11841; SN11841
|
|||||
Drug Type |
Small molecular drug
|
|||||
Therapeutic Class |
Anticancer Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C21H19N3O3S
|
|||||
Canonical SMILES |
COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
|
|||||
InChI |
InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
|
|||||
InChIKey |
XCPGHVQEEXUHNC-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 51264-14-3
|
|||||
Pharmaceutical Properties | Molecular Weight | 393.5 | Topological Polar Surface Area | 88.7 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 5 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
4
|
|||||
PubChem CID | ||||||
ChEBI ID |
ChEBI:2687
|
|||||
TTD Drug ID |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.